SUPN Supernus Pharmaceuticals, Inc.
Platform & Compounding FCF
C 54.5 / 100 composite

AlphaQuality composite grade, weighted for platform & compounding fcf businesses.

Profitability

Weight: 25%
F 18
  • 5yr Avg ROIC 3.1%
  • Operating Margin Trend -3.45 pp/yr

Capital Efficiency

Weight: 15%
D- 32
  • 5yr Avg ROE 2.8%
  • 5yr Share-Count CAGR 0.9%

Growth Quality

Weight: 25%
B 71
  • 5yr Revenue CAGR 5.5%
  • 5yr EPS CAGR 10.4%
  • Revenue-Growth Years (5) 4/5

Cash Generation

Weight: 20%
B+ 77
  • 5yr FCF Margin 17.9%
  • 5yr FCF/NI Conversion 22.64x

Balance Sheet

Weight: 10%
A+ 100
  • Net Debt / EBITDA -6.29x
  • Interest Coverage (EBIT/Int) 30.00x
  • Altman Z-Score 5.13

Stability

Weight: 5%
D+ 40
  • EPS Volatility (σ/μ) 0.60
  • Piotroski F-Score 3
  • Negative-Revenue Years (5) 1/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Trimming

2 of 2 gurus held; 2 trimmed.

Holders
2
Avg Δ position
-26.9%
New buys
0
Full exits
0
As of Q1 2026